Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition

George E Duran1,2, Yan C Wang1,2, François Moisan1, E Brian Francisco1 and Branimir I Sikic*,1

1Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA 94305, USA

Background: ABCB1 expression is uncommon in ovarian cancers in the clinical setting so we investigated non-MDR mechanisms of resistance to taxanes.

Methods: We established eight taxane-resistant variants from the human ovarian carcinoma cell lines A2780/1A9, ES-2, MES-OV and OVCAR-3 by selection with paclitaxel or docetaxel, with counter-selection by the transport inhibitor valsapodar.

Results: Non-MDR taxane resistance was associated with reduced intracellular taxane content compared to parental controls, and cross-resistance to other microtubule stabilising drugs. Collateral sensitivity to depolymerising agents (vinca alkaloids and colchicine) was observed with increased intracellular vinblastine. These variants exhibited marked decreases in basal tubulin polymer and in tubulin polymerisation in response to taxane exposure. TUBB3 content was increased in 6 of the 8 variants. We profiled gene expression of the parental lines and resistant variants, and identified a transcriptomic signature with two highly significant networks built around FN1 and CDKN1A that are associated with cell adhesion, cell-to-cell signalling, and cell cycle regulation. miR-200 family members miR-200b and miR-200c were downregulated in resistant cells, associated with epithelial to mesenchymal transition (EMT), with increased VIM, FN1, MMP2 and/or MMP9.

Conclusions: These alterations may serve as biomarkers for predicting taxane effectiveness in ovarian cancer and should be considered as therapeutic targets.

The taxane drugs docetaxel and paclitaxel are important chemotherapeutic agents for ovarian cancers, and act by stabilising microtubules, leading to cell cycle arrest or apoptosis via p53-dependent or -independent pathways (Horwitz, 1994; Dumontet and Sikic, 1999; Xiao et al, 2006).

The human ABCB1 gene, which encodes the multidrug resistance (MDR) transporter P-glycoprotein (P-gp), is expressed in the minority of ovarian cancers at diagnosis, but has been shown to be an adverse prognostic factor in some though not all studies (Baekelandt et al, 2000; Materna et al, 2004; Penson et al, 2004; Hedditch et al, 2014; Sedlakova et al, 2015). Although P-gp confers a high level of cellular resistance to many anticancer drugs, many other drug resistance mechanisms are thought to play a role in determining cellular response to taxanes including alterations of microtubule structure and dynamics, tubulin isotypes, and factors that regulate programmed cell death (Dumontet et al, 1996;...
Dumontet and Sikic, 1999; Goncalves et al, 2001; Orr et al, 2003; Esteve et al, 2006; Tommasi et al, 2007).

We have established two sets of taxane-resistant variants, one set selected in taxanes alone which express ABCB1/P-gp (Wang et al, 2006), and another set of non-MDR variants exposed to taxanes in the presence of the P-gp inhibitor valspodar. Microarray analysis was applied to all taxane-resistant variants to explore new genetic markers and mechanisms that might be useful in the prediction of sensitivity and resistance to taxane therapy. In this report, we also analysed the tubulin isotype composition and microtubule polymerisation before and after taxane drug exposure in the parental cell lines and non-MDR drug-resistant variants.

**MATERIALS AND METHODS**

**Drugs and chemicals.** Docetaxel was a gift from Sanofi Oncology (Bridgewater, NJ, USA), Novartis Pharmaceuticals provided the P-gp inhibitor valsaparod (PSC-833, PSC, East Hanover, NJ, USA), and the other anticancer drugs used in this study were obtained from the drug repository of the National Cancer Institute (Bethesda, MD, USA). Drug stock solutions were prepared in absolute ethanol at 1 mmol l⁻¹. Other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA).

**Cell lines and the development of taxane-resistance variants.** We analysed 18 ovarian carcinoma cell lines for taxane sensitivity, ABCB1 expression, and growth characteristics. Four lines (3 serous: A2780/1A9, MES-OV and OVCAR-3; and one clear cell: ES-2) were chosen as parental lines for the generation of taxane-resistant variants, and cultured as described previously (Wang et al, 2006). These lines were chosen because they were the most sensitive to taxanes, did not express high levels of ABCB1, and grew readily in vitro (doubling times of ≤48 h in standard tissue culture media). The 3 parental serous lines did not express P-gp, and the clear cell line expressed very low but detectable levels.

Each cell line was exposed to docetaxel or paclitaxel at IC₅₀ levels (the concentration required to kill 50% of the population), with or without the P-gp inhibitor valsaparod (2 mmol l⁻¹). The concentration of the taxanes used for selection of drug resistance was gradually increased until the resulting variants displayed at least a 10-fold resistance to the selecting agents. The results of selection by taxanes without a P-gp inhibitor, resulting in resistant variants expressing high levels of P-gp, have been published (Wang et al, 2006).

**SRB cytotoxicity assay.** Cytotoxicity of drugs was determined using a 72 h sulforhodamine B (SRB) assay (Spicakova et al, 2010). Each drug was tested in quadruplicate, with each experiment reproduced at least three times. The IC₅₀ values were determined directly from semi-logarithmic dose–response curves generated using the Hill equation in Kaleidagraph software (Synergy Software, Reading, PA, USA).

**Tubulin polymerisation assay.** Soluble and polymerised tubulin fractions were isolated as previously reported (Duran et al, 2015), and the percentage of tubulin polymer present in each fraction was calculated on the basis of total tubulin (soluble and polymer) present in each experimental condition as determined by densitometry.

**Flow cytometric assessment of intracellular BODIPY-labeled drugs.** The accumulation and drug content of fluorescent BODIPY-paclitaxel and BODIPY-vinblastine (both Thermo Fisher Scientific, Carlsbad, CA, USA) was determined by flow cytometry. Cells were harvested, exposed to drug for 1 h at 37 °C, drug was removed by centrifugation (200 g), and washed twice in cold PBS. For intracellular drug content, cells were allowed to efflux for an additional hour after accumulation, and were washed several times to ensure that no unbound intracellular drug remained. Drug was detected using an LSR II flow cytometer (BD Biosciences, San Jose, CA, USA).

**Microarray preparation.** mRNA from ovarian cancer cell lines was isolated using the FastTrack kit (Invitrogen Life Technologies, Carlsbad, CA, USA) and hybridised to Stanford human cDNA microarrays containing 41 421 elements, corresponding to 27 290 different UniGene cluster IDs. The hybridisations were performed as described previously, using 2 μg of sample mRNAs and 2 μg of reference mRNAs from 11 human cancer cell lines (Schaner et al, 2003). The arrays were scanned using the GenePix 4000A microarray scanner (Axon Instruments, Union City, CA, USA).

**Immunofluorescence staining.** Cells were grown on LAB-TEK II chamber slides (Thermo Fisher Scientific), fixed for 20 min in 4% (v/v) paraformaldehyde and washed several times with PBS. The cells were blocked with 2% (w/v) BSA in PBS for 1 h at room temperature, incubated in an anti-Vimentin antibody (1 : 200, Abcam, Cambridge, MA, USA) at 4 °C overnight, and recognised by a donkey anti-mouse IgG-Alexa 546 antibody (1 : 400, Thermo Fisher Scientific). The slides were dried overnight after applying ProLong Gold Antifade Mountant with DAPI (Thermo Fisher Scientific), and then visualised on a Nikon E800 fluorescence microscope (Melville, NY, USA).

**Immunoblotting.** Immunoblotting was performed using the following antibodies: anti-Vimentin (clone RV202, Abcam); anti-E-cadherin (clone 67A4, Millipore); anti-class I, pan α- and β-tubulin (Sigma-Aldrich); anti-class II and III β-tubulin (Covance); class IV β-tubulin (Abcam); and specific antibodies for acetylated α-tubulin, p53, p21 and GAPDH (Cell Signaling Technology). Membranes were then incubated with species-appropriate horse-radish peroxidase-conjugated secondary antibodies for 1 h at room temperature prior to detection using the Clarity Western ECL substrate (Bio-Rad Laboratories, Hercules, CA, USA).

**Migration assay.** Wound-healing assays were performed in triplicate measurements using the CytoSelect 24-well Wound-Healing Assay (Cell Bioslabs, Inc. San Diego, CA, USA) according to the manufacturer’s instructions. After the wound-healing inserts were removed to expose the ‘wound fields’, cells were washed with complete medium to remove dead cells and debris, followed by replacement with medium containing 2% (v/v) fetal bovine serum. Photomicrographs were taken at baseline and 24 h after the inserts were removed.

**Quantitative PCR analysis.** RT–qPCR using SYBR Green dye was performed to detect miRNA expression as described previously (Schaner et al, 2003), and amplicer sequences are listed in the Supplementary Table S2. RT–qPCR for mature miRNA was performed using miR-200b and miR-200c specific assays with the miScript System (Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions.

**Statistical analyses**

**Data normalisation and filtering.** Primary data collection was performed using GenePix Pro 3.0 (Axon Instruments). Array elements with obvious blemishes were manually flagged, and the raw data were submitted to the Stanford Microarray Database (SMD, Stanford, CA, USA). Data were background corrected, normalised using global intensity normalisation and filtered using a flag and background filter (1.5 minimal signal-over-background ratios in either channel). Only genes with at least 80% good data (fewer than 20% of array elements with blemishes or lacking target cDNA) were included in further analyses (Schaner et al, 2003). Next, the triplicate gene expression profiles of parental cell lines were averaged and the data matrix further transformed by separate centering of each parental cell line and corresponding resistant variants. A total of 31 arrays were analysed, corresponding to four
parental cell lines hybridised in triplicate, and the hybridisations of the 15 drug resistant variants and four valsapodar selected parental controls. We then proceeded with significance analysis of microarray (SAM, http://genome-www5.stanford.edu/).

Gene ontology and functional network analysis. Analyses of gene ontology, canonical pathways, and functional networks were executed using tools from Ingenuity Pathways Analysis (IPA, Ingenuity Systems, Mountain View, CA, USA). See ‘Script for Bioinformatic Analyses’ in the Supplementary Information for complete details. For network analysis, IPA computed a score $[P\text{-score} = - \log_{10}(P\text{-value})]$ according to the fit of the set of supplied genes and a list of biological functions stored in the IPKB (IPA knowledge base). The score takes into account the number of genes in the network and the size of the network to approximate how relevant this network is to the original list of genesthat allows the networks to be prioritised for further studies. A score $> 3$ ($P < 0.001$) indicates a $> 99.9\%$ confidence that a gene network was not generated by chance alone (Bredel et al, 2005).

Clinical data analysis. To explore the clinical impact of the EMT phenotype, we analysed 11 well-known EMT marker genes in 226 chemo-naïve serous ovarian cancer samples that had advanced stage (II, III and IV) and grade (2 and 3) disease (Tothill et al, 2008), and applied average linkage clustering using the Cluster software (Eisen et al, 1998). The samples were segregated into two classes based on the non-supervised hierarchical clustering ‘dendrogram’, with up- and downregulated mesenchymal markers and transcription regulators (Supplementary Figure S6A). We then performed Kaplan–Meier Survival Analysis to explore the clinical implications of the two classes using GraphPad software (Supplementary Figure S6B and C).

In vivo bioluminescence imaging. Female nude mice (Charles River Laboratories, Hollister, CA, USA) were injected either subcutaneously (S.C.) or intraperitoneally (I.P.) with $5 \times 10^6$ GLF-transduced GFP(+) OVCAR-3 parental or OVCAR-3/TP variant cells and imaged twice weekly (Moisan et al, 2014). At each time point, all mice were injected I.P. with 3 mg d-Luciferin Firefly per mouse (Biosynth International, Itasca, IL, USA), anesthetised for 10 min with isoflurane, then imaged using the IVIS Spectrum imaging system (Perkin Elmer, Waltham, MA, USA). Animal procedures were approved by Stanford University’s Administrative Panel on Laboratory Animal Care, which is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care (AAALAC International).

**Table 1. Resistance phenotype to tubulin-targeted drugs in taxane-resistant variants**

| Cell line                  | Docetaxel | Paclitaxel | Ixabepilone | Vinblastine | Vincristine | Navelbine | Colchicine |
|----------------------------|-----------|------------|-------------|-------------|-------------|-----------|------------|
| A2780/1A9/TTP50            | 10.1 ± 1.8| 30.3 ± 3.5 | 12 ± 0.23   | 0.41 ± 0.68 | 0.58 ± 0.20 | 0.31 ± 0.05 | 0.36 ± 0.078 |
| A2780/1A9/TTP80            | 15 ± 0.9  | 30 ± 3.3   | 0.82 ± 0.15 | 0.63 ± 0.12 | 0.53 ± 0.095| 0.39 ± 0.082| 0.66 ± 0.12  |
| ES-2/TTP50                 | 4.8 ± 0.35| 15 ± 1.8   | 3 ± 0.15    | 0.43 ± 0.66 | 0.28 ± 0.050| 0.42 ± 0.067| 0.90 ± 0.23  |
| ES-2/TTP80                 | 2.3 ± 2.7 | 30 ± 2.3   | 12 ± 2.1    | 0.65 ± 0.18 | 0.77 ± 0.009| 0.92 ± 0.28 | 1.8 ± 0.24   |
| MES-OV/TTP50               | 15 ± 3.3  | 20 ± 1.8   | 12 ± 1.5    | 0.52 ± 0.10 | 0.29 ± 0.048| 0.33 ± 0.052| 0.72 ± 0.11  |
| MES-OV/TTP40               | 3.3 ± 0.29| 7.1 ± 1.4  | 5.1 ± 1.0   | 0.11 ± 0.035| 0.20 ± 0.051| 0.11 ± 0.028| 0.58 ± 0.091 |
| OVCAR-3/TTP5               | 5.2 ± 0.21| 3.3 ± 0.63 | 2 ± 0.30    | 2.1 ± 0.50  | 2.4 ± 0.39  | 1.6 ± 0.29  | 1.4 ± 0.33   |
| OVCAR-3/TTP2               | 3.2 ± 0.30| 2.9 ± 0.45 | 1.1 ± 0.24  | 0.54 ± 0.11 | 0.57 ± 0.10 | 0.87 ± 0.22 | 1.4 ± 0.16   |

*Relative resistance to the respective wild-type cell line under the same conditions calculated by comparing the IC_{50} of the variant/IC_{50} of the wild-type cell line. Ratios of IC_{50}’s relative to parental cells were determined by the SRB colorimetric cell proliferation assay following 72 h drug incubations.

**RESULTS**

Taxane- and PSC-selected variants are not resistant due to transporters. Paclitaxel- and docetaxel-selected variants, counter-selected with PSC, were designated with TP and TxTP respectively. *ABCB1* expression by RT–PCR was at parental levels in each of the 8 TP and TxTP variants, and the lack of P-gp expression was confirmed by C219 immunoblotting and UIC2 staining by flow cytometry (data not shown). In addition to *ABCB1*, we also profiled 31 non-P-gp transporter genes (listed in Supplementary Online Material) in the TP and TxTP variants from the four parental lines. Expression of the non-P-gp transporters was not upregulated in these variants.

The eight TP and TxTP resistant variants displayed a non-MDR-resistant phenotype with substantial levels of resistance to taxanes (Table 1) that was not reversed by valsapodar, and no decrease in cellular taxane accumulation. Cytotoxicity dose–response curves for the 1A9/TP80 variant with and without PSC, as an example, are shown in Supplementary Figure S1. There was no consistent cross-resistance phenotype for DNA-targeted drugs among these variants, except for the two OVCAR-3 variants that showed substantial cross-resistance to doxorubicin, gemcitabine, and topotecan (Supplementary Table S1).

Reduced tubulin polymer in taxane variants and altered tubulin dynamics. The majority of the tubulin was present in the soluble form under our assay conditions, and we observed a dose-dependent increase in tubulin polymer content with acute paclitaxel exposure in the parental cell lines (1 to 10 nmolL$^{-1}$, Figure 1A–D). Under identical experimental conditions, there was a reduction in tubulin polymer present in the all eight taxane-resistant variants compared to the parental controls, and in three of these variants (1A9/A2780, ES-2 and MES-OV), treatment with paclitaxel did not result in tubulin polymer expression up to the highest paclitaxel concentration tested (Figure 1A–C).

There was an inverse correlation ($R^2 = 0.98$) between the percentage of tubulin polymer present in the four untreated parental cell lines and paclitaxel activity determined by IC_{50} in SRB assays, with the cell line having the most tubulin polymer being the most sensitive to paclitaxel (OVCAR-3), and the least sensitive having an undetectable amount of tubulin polymer (MES-OV, Figure 1E). In OVCAR-3 cells, we observed a reduction in tubulin polymer in the OVCAR-3/TxTP5 and OVCAR-3/TTP20 variants, and the effects of paclitaxel were reduced compared to parental OVCAR-3 (Figure 1D and F).

Reduced tubulin polymer is associated with reduced intracellular taxane content. Although the non-MDR taxane variants

DOI:10.1038/bjc.2017.102
accumulated equivalent levels of taxanes relative to parental controls (data not shown), five out of eight variants had reduced intracellular BODIPY-taxane compared to parental controls (Figure 2). The association between resistance to paclitaxel as measured by the IC50 and drug content was inversely correlated ($r^2 = 0.84$). Conversely, seven of eight variants that were hypersensitive to the effects of tubulin destabilisers (Table 1) demonstrated elevated BODIPY-vinblastine relative to parental controls ($r^2 = 0.72$). One outlier is the OVCAR-3/TxTP5 variant that demonstrated a unique phenotype of resistance to both tubulin polymerising and destabilising agents.

Elevated TUBB3 content in the majority of the variants. Tubulin content was profiled by RT–qPCR and confirmed by immunoblotting with tubulin class-specific antibodies. We observed a reduction in the predominant $\beta$-tubulin isotype (class I, TUBB, Figure 3) in seven variants compared to parental controls and normalised to both GAPDH expression and to total protein using Stain-Free TGX gels (Bio-Rad Laboratories). Although we observed reduced TUBB content, no mutations in the isotype were detected by Sanger DNA sequencing in both forward and reverse directions, and by denaturing high-performance liquid chromatography (Sale et al, 2002), data not shown. The expression of $\beta$-tubulin classes II and IV was low to undetectable depending on the cell lines tested. Six variants had elevated class III (TUBB3) expression following drug selection, but overall pan $\alpha$- and $\beta$-tubulin expression appeared stable compared to parental cell lines. Finally, when stabilised by taxanes, microtubules are acetylated (Gu et al, 2016), and we observed a reduction in total acetylated $\alpha$-tubulin (Lys40) in all taxane variants (data not shown).

Supervised gene expression analysis identifies EMT and cell cycle regulators associated with non-MDR taxane resistance. We applied a two-group SAM analysis to identify differentially expressed genes between the non-MDR taxane variants and control samples (parental cell lines and PSC alone-selected cells), and we identified 1304 clones (951 clones upregulated, 353 downregulated, Figure 4A) that clearly separated the two groups. Among the upregulated clones, 9.6% were associated with the extracellular region or cell adhesion. Of these, SPOCK1 and FN1 were the top genes upregulated in non-MDR-resistant variants ($d$-scores 3.84 and 3.38, respectively, $q$-value 0%). FN1 is an important
mesenchymal element participating in epithelial to mesenchymal transition (EMT; Mikheeva et al., 2010), and SPOCK1 is one of the EMT-Core-Signature genes identified by Taube et al. (2010). Other upregulated extracellular matrix (ECM)-interacting genes included N0V, MMP2, MMP16, CDH6, COL12A1, COL15A1, LTF, LUM, ITGB8 and CASK. SAM also identified genes involved in cell cycle regulation and cytoskeleton organisation, including upregulated CDKN1A (p21), TP53INP and TN1K, and downregulated TERT, MCM3, CDK2, RCCI, CDC6, NPM1 and CDC16. Several cytokine related genes were overexpressed in non-MDR models, such as IL1F5, IL15, IL16 and TLR1, suggesting the involvement of proinflammatory elements in non-MDR resistance. Cells grown in PSC alone did not develop an EMT phenotype, and their gene expression clustered with parental cells not exposed to drugs.

Network analysis reveals two key networks: FNI and CKNA1. To explore how the transcripts identified by SAM are related, the 1304 clones from SAM were first mapped to non-redundant elements in the Ingenuity knowledge base, and networks of interacting genes and their products were dynamically computed. The most significant enrichment was found for the genes involved in the function of cellular growth and proliferation (195 genes), cellular development (149 genes), cell cycle (86 genes), cell–cell signalling and interaction (15 genes), and cell death (168 genes), Supplementary Table S3. Network analysis identified two highly significant networks with significance scores of 48 and 27 (Supplementary Table S4), one network built around FNI and another around CDKN1A (Figure 4B).

EMT phenotype is associated with non-MDR taxane resistance. In addition to FNI and MMP2 that were identified by genomic profiling, we confirmed the expression of several other EMT-associated genes using RT–qPCR. MMP9 was markedly overexpressed in six variants at a range of 2- to 14-fold higher than controls (Supplementary Figure S2). FNI as a mesenchymal marker was identified by SAM analysis as a top upregulated gene in the non-MDR signature, and elevated expression was confirmed in the MES-OV and OVCAR-3 variants. VIM mRNA expression was increased in several resistant variants, and elevated Vimentin mRNA content was confirmed by immunoblotting in all eight resistant variants (Figure 5A) and by fluorescent immunocytochemistry in the OVCAR-3/TP cells (Figure 5B). Decreased E-cadherin protein was not concordant with the decreased Vimentin, with E-cadherin decreased in four and increased in four variants (Figure 5A). Cellular migration was markedly increased in the taxane variant of OVCAR-3 at 24 h compared to parental control as determined by a wound-healing assay (Figure 5C). Overall, six of the eight resistant variants manifested a strong EMT phenotype.

Of note, we did not find differences in mechanisms of resistance between the paclitaxel (TP) and docetaxel (TxTP) selected variants. EMT profiles were similar, and the TP and TxTP variants clustered together in hierarchical clustering of the microarrays. Altered miRNA 200 family members and apoptotic regulators. Cellular responses to taxanes are governed by several known factors. In particular, increasing evidence indicates an association
between decreased expression of members of the miR-200 family, EMT, and increased TUBB3 expression and taxane resistance (Park et al., 2008; Cochrane et al., 2009; Hu et al., 2009). We observed a marked decrease in both miR-200b and miR-200c in five of the resistant variants and a moderate decrease in another (Supplementary Figure S3). We examined the expression of apoptotic regulatory genes, and six of the eight resistant variants manifested increased BCL-2 and MCL-1 content by qPCR (Supplementary Figure S4). Both OVCAR-3/TP and TxTP variants have upregulated BCL-XL. The proapoptotic gene BAX was below control levels in two resistant variants.

**TP53 status and non-MDR taxane resistance.** We assessed the TP53 status of these cells and their response to the DNA damaging drug doxorubicin (Dox), Supplementary Table S5 and Supplementary Figure S5. Treatment with Dox resulted in p53 accumulation in the 1A9/A2780 cell line and its taxane variants and downstream activation of p21, indicating a functional p53. ES-2, MES-OV, and OVCAR-3 cells and their variants had high levels of p53 with and without Dox. We could not detect p21 following DNA damage in ES-2, and p21 levels were low in MES-OV and OVCAR-3. Sequencing TP53 revealed mutations in ES-2 (Exon 7: Ser-241 to Phe, TC843C → TTC) and MES-OV (Exon 8: TC843C → TTC).

Figure 4. Hierarchical clustering of supervised analysis by SAM differentiated taxane-resistant variants from parental cells. 28 225 clones were analysed by SAM, resulting in 1304 clones representing significantly differentially expressed genes between non-MDR and control samples (A). Differentially expressed genes are shown in Treeview. Each row represents a separate cDNA clone on the microarray, and each column represents a separate mRNA sample. Bright red represents the highest levels and bright green the lowest levels of expression. In each sample, the ratio of abundance of transcripts of each clone to its cell line adjusted mean abundance is depicted according to the colour scale shown at the bottom. The dendrogram at the top of the figure represents the hierarchical clustering of the samples based on similarity in their patterns of gene expression. Functional networks were identified using Ingenuity Pathways Analysis of genes identified by SAM. Depicted are network maps of molecular interactions and subcellular distribution of two networks, FN1 and CDKN1A, that distinguish taxane-resistant from drug sensitive cells (B). Nodes represent genes, with their shapes representing the functional classes of the gene products, and edges indicate the biological relationship between the nodes, which include physical and functional interactions. Nodes are colour-coded according to their d-score from SAM (red, overexpressed in TP and TxTP variants; green, underexpressed in TP and TxTP variants).
Arg-282 to Trp, C965GG→CAG). In OVCAR-3 cells, we confirmed a single TP53 mutation resulting in Arg-248 to Gln substitution (CG864G→CAG). Overall, there was no difference between parental cells and their taxane-resistant variants in this pathway.

**Proliferative potential in taxane variants.** The cellular doubling times in vitro were prolonged two-fold in three of the four resistant variants OVCAR-3TP, MES-OVCAR-3/TP and ES-2/TP, compared to the parental and valspodar treated cells (Supplementary Figure S6). The TxTP resistant variants also exhibited slower growth (data not shown). However, the growth of the resistant TP variants as xenografts in athymic nude mice was faster than the parental xenografts (Supplementary Figure S7).

**Clinical implications of EMT genes in ovarian cancer samples.** We examined the expression of 11 EMT genes in publicly available microarray data from ovarian cancer samples (Tothill et al, 2008). To facilitate the analysis, we organised the gene expression patterns and samples by non-supervised hierarchical clustering and visualised in Treeview (Supplementary Figure S8A; Eisen et al, 1998). Remarkably, we observed a predominantly biphasic pattern
of expression for the EMT genes in 226 chemonaive serous ovarian cancer samples comprising advanced stage and grade tumours. The biphasic profile allowed a natural separation of these tumours into two classes—upregulated and downregulated. The mesenchymal markers VIM, MMP2, SPOCK1, FN1, SPARC and MMP9 and the transcription regulators, ZEB1, ZEB2, SNAI2 and TWIST1 displayed similar expression pattern: upregulated in 105 samples and downregulated in 121 samples; but CDH1, the hallmark of EMT, showed an opposite expression pattern in most of the samples compared to the mesenchymal markers and transcription regulators. To explore the clinical implications of the observed EMT signatures, we ran Kaplan–Meier survival analysis to compare the two classes of samples. Compared to the downregulated class, tumours in upregulated class were significantly more likely to progress to metastasis and death in a 5-year follow-up period ($P = 0.0008$ and 0.036 respectively, Supplementary Figure S8B and C).

**DISCUSSION**

The selection of drug resistance by exposure to taxanes alone in vitro results in transporter mediated mechanisms with ABCB1 gene activation (P-gp) in the majority of cases (Wang et al, 2006). The prevalence of P-gp selection likely results from the high stringency of the selection process and the high degree of resistance conferred by P-gp. Since ABCB1 expression is of uncertain clinical significance in ovarian cancers, including those resistant to taxanes, in this study we developed non-MDR-resistant variants by co-exposure of a panel of ovarian cancer cell lines to a taxane plus the P-gp inhibitor PSC. This 'counter selection' by PSC provided the desired stable, non-MDR, taxane-resistant variants to further study mechanisms of resistance to taxanes. A summary table of the alterations in these taxane plus PSC selected variants is presented as Supplementary Table S6. Remarkably, but not surprisingly, all eight of the resistant variants selected demonstrated alterations in baseline and taxane-stimulated tubulin polymerisation (Dumontet and Sikic, 1999). This reduction in tubulin polymer was the common feature of all of the variants, hence a 'hallmark,' and in six of the eight was associated with increased class III $\beta$-tubulin expression. This finding related to selection for resistance also emphasises the central role of microtubule dynamicity in the mechanism of action of taxane drugs (Horwitz, 1994; Blagosklonny and Fojo, 1999; Orr et al, 2003).

Class III $\beta$-tubulin (TUBB3) is an important gene in taxane resistance and it is also a direct target of miR-200c (Cochrane et al, 2009). Although TUBB3 was not identified as a differentially expressed gene associated with non-MDR resistance by genomic profiling, we reasoned that the cDNA platform we used might not be sensitive enough to discern the highly homologous tubulin isoforms. Therefore, we performed immunoblotting with isoform-specific antibodies, and found elevated class III $\beta$-tubulin in six of eight resistant variants, indicating that TUBB3 may contribute to taxane resistance in these cells (Figure 3A). The most abundant $\beta$-tubulin tubulin isoform, TUBB (class I), was downregulated in the CDKN1A network, and its downregulation in all the variants was confirmed by RT–qPCR (data not shown) and by immunoblotting (Figure 3).

TUBB3 acts by reducing microtubule polymerisation, thus resulting in lower drug binding of docetaxel to microtubules (Hari et al, 2003). In our study, an inverse correlation between the resistance to paclitaxel and intracellular taxane content was highly significant (Figure 1). Furthermore, the majority of these variants are hypersensitive to tubulin destabilising drugs, and we observed higher vinblastine content in these variants compared to parental cells. The OVCAR-3/TxTP5 variant differs from the others in that it is resistant to both microtubule polymerising and tubulin destabilising agents, and has increased intracellular paclitaxel and vinblastine compared to parental OVCAR-3 cells.

We used genomic analysis to explore other alterations in these variants. SAM identified 1304 transcripts that have distinct expression profiles between non-MDR taxane-resistant variants and parental cells. The signature includes genes involved in EMT, ECM remodelling, and cell cycle regulation. Several mesenchymal elements were confirmed by qPCR to be overexpressed in resistant cells, including FN1, VIM, SPARC, MMP9, and MMP2. The mesenchymal phenotype was found in six of the eight non-MDR variants selected by taxanes. FN1 was identified as a top-scoring up-regulated gene in non-MDR variants. The Ingenuity network built around FN1 mainly involved regulation of cellular movement and cell-to-cell signalling. Fibronectin is involved in cell adhesion and migration processes. Its expression is correlated significantly with tumour stage in ovarian carcinomas, and has an adverse influence on overall survival (Franke et al, 2003). Overexpression of FN1 confers resistance to multiple chemotherapeutic agents in vivo and in vitro in a variety of cell lines and tissues (Damiano et al, 2001; Haslehurst et al, 2012). These results highlight a role of extracellular matrix (ECM) proteins, particularly FN1, in conferring drug resistance in human cancers. ECM provides a survival advantage for tumour cells and promotes resistance in lung and ovarian cancer cells (Sethi et al, 1999; Sherman-Baust et al, 2003).

FN1 is upregulated in EMT, a cellular trans-differentiation program that enables epithelial cancer cells to acquire a mesenchymal phenotype associated with high-grade malignancy, i.e. the ability to invade and metastasise (Taube et al, 2010). During EMT, downregulation of E-cadherin by regulators such as SNAI1, SNAI2, ZEB1 and ZEB2 results in the loss of cell-to-cell adhesion. A few studies have demonstrated an association between underexpressed E-cadherin and poorer survival rate in ovarian cancer patients (Davidson et al, 2000; Faleiro-Rodrigues et al, 2004). Cancer cells that have undergone EMT show increased resistance to apoptosis and paclitaxel (Kajiyama et al, 2007). Enhanced metastatic ability and chemoresistance are frequently concurrent during the therapeutic course, and are the major causes of poor prognosis of ovarian cancer patients. In our taxane-resistant models, the highly upregulated mesenchymal genes FN1 and MMP2 were associated with non-MDR taxane resistance. SNAI2 and ZEB2, master transcription regulators for EMT, were overexpressed in several resistant variants (data not shown). Furthermore, markedly increased migration potential was observed in the resistant cells. The downregulation of E-cadherin was confirmed by qPCR in the resistant variants (data not shown).

Upregulated MMP14 and MMP16 were observed in the FN1-associated network. MMP14 (MT1-MMP) mediates the activation of MMP2 (Sato et al, 1994). Upregulation of MMP14 and MMP16 (MT3-MMP) is involved in EMT (Gilles et al, 1997; Pulyaeva et al, 1997), and associated with the aggressiveness of human ovarian, breast and gastric cancer (Pulyaeva et al, 1997; Lowry et al, 2006; Moss et al, 2009). K-cadherin (CDH6) was also identified by our SAM analysis to be upregulated in the resistant models. The overexpressed mesenchymal cadherins may have a dominant effect in cell–cell interactions, and enhance the motility of tumour cells even in the presence of E-cadherin (Voulgari and Pintzas, 2009). The mesenchymal cell–matrix adhesion system is principally based on the integrin family, and several integrins were shown to be associated with EMT (Voulgari and Pintzas, 2009).

The miR-200 family is a marker for epithelial cells and a regulator of EMT (Park et al, 2008; Cochrane et al, 2009). MiR-200 maintains ‘epithelial-ness’ by directly targeting and suppressing ZEB1 and ZEB2. Downregulation of the miR-200 family contributes to tumour metastasis (Park et al, 2008), and FN1 has been
identified as a novel target of miR-200c (Howe et al, 2011). Re-expression of miRNAs of the miR-200 family reduced expression of its target genes, including ZEB1, ZEB2, FNI and class III β-tubulin (TUBB3), and inhibited ovarian cancer cell migration and invasion (Cochrane et al, 2009; Fu et al, 2009). MiR-200c was shown to mitigate invasiveness of ovarian cancer cells and restore sensitivity to taxanes (Cochrane et al, 2009; Brozovic et al, 2015). In our study, miR-200b and miR-200c were downregulated in six of the resistant variants, and inverse expression pattern was observed between the miR-200 family members and mesenchymal genes. We have previously reported were downregulated in six of the resistant variants, and inverse expression compared to quiescent cells (Shah and Schwartz, 2001). In chemotherapy, and taxanes are more effective against proliferating than quiescent cells, and inhibition of p21, and an ability to undergo p21-induced cell cycle arrest may explain in part the intrinsic chemotherapy resistance of mature teratomas (Mayer et al, 2003). Indeed, we observed substantial decreases in cell growth rate in resistant variants, with greater decreases seen in OVCA-3/TP, MES-OV/TP and ES-2/TP cell lines. This decreased growth rate likely further contributed to the taxane-resistance phenotype of these cells.

**BCL-2, BCL-XL, MCL-1 and BAX** are determinants of apoptosis in response to chemotherapeutic agents, and are variably expressed in ovarian cancers (Jones et al, 1998; Chun and Lee, 2004). The anti-apoptotic gene BCL-2 was overexpressed in six of the eight resistant variants. Marked upregulation was seen in MES-OV taxane-resistant cells, with the greatest increase in MES-OV/TaxTP, which was 62-fold higher than drug sensitive controls. MCL-1 was also upregulated in six resistant variants, while two variants had reduced proapoptotic BAX content. BCL-XL was upregulated in the OVCA-3/TP and TaxTP variants, notable because of their cross-resistance to the DNA damaging drugs doxorubicin, gemcitabine, and topotecan (Supplementary Table S1). Although these changes in apoptotic genes may contribute to the taxane resistance of these variants, most of the variants did not show a broad cross-resistance phenotype.

Ovarian cancers with upregulated EMT genes conferred worse clinical outcomes, and had significantly shorter relapse-free and overall survival. Interestingly, the high stromal response subtype tumours (C1 group) identified by Tothill were all grouped in the red-cluster (upregulated). C1 was shown to have the poorest survival outcome as a group (Tothill et al, 2008).

In conclusion, we have developed a set of eight novel non-MDR taxane-resistant models by co-selection of ovarian cancer cells with taxane drugs and a P-gp inhibitor. The phenotypes of these resistant variants are complex, and include decreased tubulin polymerisation, elevated expression of TUBB3, EMT, a decreased rate of proliferation, and alterations in apoptosis regulatory genes. These alterations are linked to some extent at the regulatory level, that is, via the miR-200 family, but may also reflect independent selection events during prolonged drug selections. The EMT phenotype of ovarian cancer cells along with TUBB3, tubulin polymer, and apoptotic genes may serve as biomarkers for responsiveness to taxanes, and modification of these markers should be considered as therapeutic targets in cancers.

**ACKNOWLEDGEMENTS**

Financial support was provided by NIH grants R01 CA114037 and R01 CA184968 from the US Public Health Service (BI Sikic).

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**AUTHOR CONTRIBUTIONS**

Conception and design: GED, YCW, BIS. Development of methodology: GED, YCW, FM. Acquisition of data: GED, YCW, FM, EBF. Analysis and interpretation of data: GED, YCW, FM, BIS. Writing, review and/or revision of the manuscript: GED, YCW, BIS.

**REFERENCES**

Abbas T, Dutta A (2009) p21 in cancer: intracellular networks and multiple activities. Nat Rev Cancer 9(6): 400–414.

Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB (2000) P-glycoprotein expression is a marker for chemotherapeuticsensitivity and prognosis in advanced ovarian cancer. Anticancer Res 20(2B): 1061–1067.

Blagosklonny MV, Fojo T (1999) Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83(2): 151–156.

Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI (2005) Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65(19): 8679–8689.

Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI (2015) The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCA-3 and MES-OV cells. Mol Oncol 9(8): 1678–1693.

Chun E, Lee KY (2004) Bcl-2 and Bcl-XL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 315(3): 771–777.

Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK (2009) MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther 8(5): 1055–1066.

Damiano JS, Hazlehurt LA, Dalton WS (2001) Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 15(8): 1232–1239.

Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Byne M, Goldberg I, Kopolovic J, Berner A (2000) E-Cadherin complex protein expression and survival in ovarian carcinoma. Gynecol Oncol 79(3): 362–371.

Dumontet C, Duran GE, Steger KA, Becetic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56(5): 1091–1097.

Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17(3): 1061–1070.

Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J, Brassard D, Vrignaud P, Sikic BI (2015) Mechanisms of resistance to cabazitaxel. Mol Cancer Ther 14(1): 193–201.

Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95(25): 14863–14868.

Esteve MA, Carre M, Bourgarel-Rey Y, Kruczyznki A, Raspaglio G, Ferlini C, Beauger D (2006) Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther 5(11): 2824–2833.
Tubulin polymerisation and taxane resistance

www.bjcancer.com | DOI:10.1038/bjc.2017.102

3.5.

Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, Stack MS (2009)
Ovarian cancer cell detachment and multilayered aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in Lp. metastatic dissemination. *Cancer Res* 69(17): 7121–7129.

Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB (2003) Mechanisms of Taxol resistance related to microtubules. *Oncogene* 22(47): 7780–7785.

Park SM, Gaur AB, Lengyl E, Peter ME (2008) The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. *Genes Dev* 22(7): 894–907.

Penson RT, Oliva E, Skates SJ, Grypits T, Fuller Jr AF, Goodman A, Seldin MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. *Gynecol Oncol* 93(1): 98–106.

Pulyaeva H, Bueno J, Polette M, Birembaut P, Sato H, Seiki M, Thompson EW (1997) MT1-MMP correlates with MMP-2 activation potential seen after epithelial to mesenchymal transition in human breast carcinoma cells. *Clin Exp Metastasis* 15(2): 111–120.

Sale S, Sun R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI (2002) Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. *Mol Cancer Ther* 1(3): 215–225.

Sato H, Takino T, Okada Y, Cao J, Shingnawa A, Yamamoto E, Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. *Nature* 370(6484): 61–65.

Schaner ME, Ross DT, Ciareggio V, Sorlie T, Troyanskaya O, Diehn M, Wang YC, Duran GE, Sikic TL, Caldeira S, Skomedal H, Tu IP, Hernandez-Boussard T, Johnson SW, O’Dwyer PJ, Fero MJ, Kristensen B, Borresen-Dale AL, Hastie T, Shibirani R, van de Rijn M, Teng NN, Longacare TA, Botstein D, Brown PO, Sikic BI (2003) Gene expression patterns in ovarian carcinomas. *Mol Biol Cell* 14(11): 4376–4386.

Segallkova T, Laco J, Calvota K, Cervinkova M, Tosner J, Rezac A, Spacek J (2015) Clinical significance of the resistance proteins LRP, Pgp, MRPI, MRP3, and MRPS in epithelial ovarian cancer. *Int J Gynecol Cancer* 25(2): 236–243.

Sethi T, Rintoul RC, Moore SM, Mackinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strier R, Haslett C (1999) Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. *Nat Med* 5(6): 662–668.

Shah MA, Schwartz GK (2001) Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. *Clin Cancer Res* 7(8): 2168–2181.

Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ (2003) Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. *Cancer Cell* 3(4): 377–386.

Spicakova T, O’Brien MM, Duran GE, Sweet-Cordero A, Sikic BI (2010) Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. *Mol Cancer Ther* 9(11): 2970–2981.

Taube JH, Herschikowitz II, Komurov K, Zhou Y, Gupta S, Yang J, Hertwk K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA (2010) Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metastatic breast cancer subtypes. *Proc Natl Acad Sci USA* 107(35): 15449–15454.

Tommasi S, Mangia A, Llacalimita R, Bellizzi A, Fedele V, Cirriatti A, Thomsen C, Kondzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins. *Int J Cancer* 120(10): 2078–2085.

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locando B, Traficiante N, Fereday S, Hung JA, Chiew YE, Haviv I, Australian Ovarian Cancer Study G, Gertig DE, Rockall T, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins. *Int J Cancer* 120(10): 2078–2085.

Vougiar A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. *Biochim Biophys Acta* 1796(2): 75–90.
Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK, Chen X, Sikic BI (2006) Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. *Genes Chromosomes Cancer* 45(4): 365–374.

Xiao H, Verdier-Pinard P, Fernandez-Fuentes N, Burd B, Angeletti R, Fiser A, Horwitz SB, Orr GA (2006) Insights into the mechanism of microtubule stabilization by Taxol. *Proc Natl Acad Sci USA* 103(27): 10166–10173.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)